C4 Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $35.9 | $35.6 | $20.8 | $31.1 | $45.8 |
| Operating income | -$115.2 | -$119.6 | -$139.0 | -$129.5 | -$82.1 |
| Net income | -$105.0 | -$105.3 | -$132.5 | -$128.2 | -$83.9 |
| Balance Sheet | |||||
| Total debt | — | — | — | $12.5 | $12.5 |
| Cash Flow Statement | |||||
| Free cash flow | -$99.3 | -$65.3 | -$108.5 | -$111.4 | -$88.2 |
| Share repurchases | $0.2 | $0.2 | $0.1 | $0.0 | — |
Shares outstanding 110.6M · Free float 87.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.